RASA1 and osteosarcoma: WT KRAS tumors with GAP deficiencies that induce an elevated proportion of active GTP-bound KRAS may be sensitive to daraxonrasib, a possibility that could further expand the use of daraxonrasib for new patient populations with osteosarcoma and beyond.